(RTTNews) - The following are some of today's top gainers in the healthcare sector.
1. ACADIA Pharmaceuticals Inc. (ACAD)
ACADIA is a revenue-generating biopharmaceutical company developing and commercializing innovative medicines to address unmet medical needs in central nervous system disorders.
Gained 63.24% to close Monday's (Sep.9) trading at $38.85.
News: The Company's phase III study evaluating Pimavanserin for the treatment of dementia-related psychosis, dubbed HARMONY, is all set to be stopped early for positive efficacy.
The trial has met its primary endpoint, demonstrating a highly statistically significant longer time to relapse of psychosis with Pimavanserin compared to placebo in a planned interim efficacy analysis.
Pimavanserin is already approved in the U.S., under brand name NUPLAZID, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The drug brought home net sales of $83.2 million in the second quarter ended June 30, 2019, up 46% over the year-ago same quarter.
2. American Renal Associates Holdings Inc. (ARA)
American Renal Associates is a dialysis services provider in the United States.
Gained 31.54% to close Monday's trading at $10.26.
News: No news
-- On September 5, 2019, the Company announced that it has completed its required periodic filings, say the Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and Quarterly Reports on Form 10-Q for the first and second fiscal quarters ended March 31, 2019 and June 30, 2019, and is back in compliance with its listing requirements under New York Stock Exchange rules.
For 2019, the Company expects total normalized treatment growth to be in a range of 7.0% to 7.5%, compared to 6.1% in 2018. Revenue per treatment for 2019 is anticipated to decline by 2% to 3%, as compared to $349 in 2018.
3. Eyenovia Inc. (EYEN)
Eyenovia is a clinical-stage, ophthalmic biopharmaceutical company.
Gained 22.29% to close Monday's trading at $4.17.
News: The Company is all set to make a presentation at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019.
Clinical Trials & Near-term Catalysts:
-- On January 30, 2019, the Company announced that its phase III study evaluating MicroStat for pharmacologic mydriasis (eye dilation), dubbed MIST-1, met the primary endpoint. -- On February 25, 2019, the Company announced positive results from MIST-2, its second phase III study in the MicroStat program for pharmacologic mydriasis. -- A phase III study of MicroPine for the reduction of progressive myopia using Eyenovia's proprietary atropine topical micro-formulation delivered by the Optejet dispenser, dubbed CHAPERONE, is underway.
4. Paratek Pharmaceuticals Inc. (PRTK)
Paratek Pharma is a biopharmaceutical company focusing on drugs that target infectious disease and other difficult to treat conditions.
Gained 18.25% to close Monday's trading at $4.60.
News: The Company made a presentation at 21st Annual H.C. Wainwright Global Investment Conference on Monday, September 9, 2019.
Products & Pipeline:
** The Company has one FDA-approved drug NUZYRA for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). ** NUZYRA is under review in the European Union, and a decision is expected in the second half of 2019. ** Two phase II studies of NUZYRA in urinary tract infections are underway - with topline data expected in the fourth quarter of 2019.
5. Cesca Therapeutics Inc. (KOOL)
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies.
Gained 16.81% to close Monday's trading at $4.10.
News: The Company announced that it has signed an exclusive, global distribution agreement to supply its X-Series cell processing products to a major life sciences distributor who will market them globally.
The X-Series products are major components of the Company's CAR-TXpress™ platform, a semi-automated, closed cellular processing platform used for high-efficiency cell purification and cell washing. The X-Series products, when used in combination with the Company's proprietary buoyancy activated cell sorting (BACS) technology, can be applied for both research and commercial manufacturing of a large variety of cell-based therapeutics, including chimeric antigen receptor-T (CAR-T) cells.
6. Ardelyx Inc. (ARDX)
Ardelyx is a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases.
Gained 15.40% to close Monday's trading at $5.62.
News: No news
On September 3, 2019, the Company announced positive results from AMPLIFY, a pivotal phase III study, which evaluated its investigational drug Tenapanor in combination with phosphate binders in patients with chronic kidney disease on dialysis whose hyperphosphatemia was not previously controlled with binders alone.
-- A phase III monotherapy study of Tenapanor in end-stage renal disease patients on hemodialysis and peritoneal dialysis, dubbed PHREEDOM, is underway, with results expected in the fourth quarter of this year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.